For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Where to buy · live market data

Who's worth your money for Tesamorelin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 45 scored sellers

$3.40/mg

$67.99 · 20mg · 99.0% purity

14 COAs
Buy Code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$1.89/mg

$378 · 200mg · 99.9% purity

Most tested

28 independent COAs on file

$4.49/mg

$898 · 200mg · 99.8% purity

Average price

$6.83/mg

Sellers

77

45-day trend

-28.7%

68 of 77 sellers have a current price· 4 stale hidden· 19 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tesamorelin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tesamorelin

CAS

218949-48-5

Molecular formula

C221H366N72O67S

Sequence

YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL

Typical dose range

2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC

Half-life

~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)

Independent evidence

COAs for Tesamorelin

342 third-party tests across 53 vendors. Each card links to the full report.

All 342 COAs for Tesamorelin →
Measured purity 79.8%–100.0% across 212 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.49 %
Sep 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by VeratisBio· batch TESA0001

Aggregated · 3rd-party listing
99.73 %
Sep 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Novaglo Research· batch 5003091526TM

Aggregated · 3rd-party listing
99.90 %
Sep 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 29310L-DK

Aggregated · 3rd-party listing
99.64 %
Sep 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM20-06

Aggregated · 3rd-party listing
99.37 %
Sep 2026
Vanguard Laboratory Strong

For

Tesamorelin

by Virtus Peptides· batch ZQ-20260809-TSM10-GREEN

Aggregated · 3rd-party listing
99.00 %
Sep 2026
Ethos Analytics Strong

For

Tesamorelin

by Glacier Aminos· batch TES10GA-08

✓ Vendor-published
99.90 %
Sep 2026
BTLabs Moderate

For

Tesamorelin

by Sunrise Bioresearch· batch A36JHMQ

COA on file
Aggregated · 3rd-party listing
99.87 %
Aug 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Novaglo Research· batch 5003082126TM

Aggregated · 3rd-party listing
99.62 %
Aug 2026
ILS Labs Strong

For

Tesamorelin

by Frontier Aminos· batch TSM-14

Aggregated · 3rd-party listing
99.03 %
Aug 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by NovaForge Labs· batch NFL-0002

Aggregated · 3rd-party listing
99.43 %
Aug 2026
ILS Labs Strong

For

Tesamorelin

by Velora Biolabs· batch VBL-TSM10-1

Aggregated · 3rd-party listing
99.39 %
Aug 2026
ILS Labs Strong

For

Tesamorelin

by Velora Biolabs· batch VBL-TSM20-1

Aggregated · 3rd-party listing
99.95 %
Aug 2026
Janoshik Analytical Limited

For

Tesamorelin

by Longeva· batch PM-260719-TESAMORELIN-01

Aggregated · 3rd-party listing
99.78 %
Aug 2026
ILS Labs Strong

For

Tesamorelin

by NovaForge Labs· batch TSM-QSCT1

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Tesamorelin

by VoriLabs· batch TES-2607-A

Aggregated · 3rd-party listing
97.10 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.31 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by Virtus Peptides· batch NS-20260601 | TSM10-WHITE

Aggregated · 3rd-party listing
99.12 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NovaForge Labs· batch Lot - 2026 - 1

Aggregated · 3rd-party listing
98.87 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by Artisan Aminos· batch AA-TSM10-049

Aggregated · 3rd-party listing
99.86 %
Jul 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 160-310X-DK

Aggregated · 3rd-party listing
99.60 %
Jul 2026
BTLabs Moderate

For

Tesamorelin

by VoriLabs· batch TES-2606-A

Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM-13

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Optima Supply· batch OS-2026-1763

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Hydro Research Peptides· batch HR-2026-4509

Research depth

23 citations indexed for Tesamorelin

All research on Tesamorelin →

Study · 2026

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol

Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

meta-analysis · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

meta-analysis · 2026

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis

BackgroundHIV-associated lipodystrophy, a complication of combined antiretroviral therapy (CART), causes significant physical and psychological distress in people living with HIV (PLWH), compromising treatment adherence.